Clinical trial
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
NCT00054470 · The University of Texas Health Science Center at San Antonio, Other · Withdrawn
Key facts
| NCT number | NCT00054470 |
|---|---|
| Title | Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase II Evaluation Of The Efficacy And Safety Of R115777 (NSC702818) A Non-Peptidomimetic Farnesyl Transferase Inhibitor, And Trastuzumab In Patients With Advanced Breast Cancer |
| Lead sponsor | The University of Texas Health Science Center at San Antonio, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, tipifarnib |
| Enrollment | 0 |
| Start date | Dec 1, 2002 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Feb 6, 2003 |
| Last update posted | Jun 29, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: